Navigation Links
Cornell Researchers Identify a Weak Link in Cancer Cell Armor
Date:11/12/2009

The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Researchers at the Cornell University College of Veterinary Medicine have discovered that inactivation of a DNA repair gene called Hus1 efficiently kills cells lacking p53 -- a gene mutated in the majority of human cancers.

Ithaca, NY (Vocus) November 12, 2009 -- The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Researchers at the Cornell University College of Veterinary Medicine have discovered that inactivation of a DNA repair gene called Hus1 efficiently kills cells lacking p53 -- a gene mutated in the majority of human cancers.

Using a mouse model, senior author Robert Weiss, associate professor of molecular genetics, first author and graduate student Stephanie Yazinski and colleagues explored how cells respond when both genes are inhibited. When they inactivated the Hus1 gene in healthy mammary gland tissues, the researchers report, it caused genome damage and cell death. And when they studied the effects of Hus1 inactivation in p53-deficient cells, which are highly resistant to cell death, they discovered that the ability of Hus1 inactivation to kill cells was even greater.

The study is published in the Nov. 9 issue of the Proceedings of the National Academy of Sciences.

"Our work contributes to an important new understanding of cancer cells and their weaknesses," Weiss said. "The mutations that allow cancer cells to divide uncontrollably also make the cancer cells more dependent on certain cellular processes. We were able to exploit one such dependency of p53-deficient cells and could efficiently kill these cells by inhibiting Hus1."

Weiss and his team have new experiments under way.

"We've proven the power of inhibiting both pathways in normal tissue," said Weiss. "Now we want to extend our knowledge to cancerous tissue and determine if the loss of Hus1 will impact the ability of cancers with p53 mutations to take hold and grow."

Weiss's research was funded by the National Institutes of Health and is now funded through 2013 in part by the American Recovery and Reinvestment Act (ARRA). To date, Cornell has received 124 ARRA grants, totaling more than $99.9 million. Weiss's ARRA funding will support one faculty and two student positions as well as the research activities of several additional lab members.

Written by Stephanie Specchio, communications director for the College of Veterinary Medicine. This article originally appeared in the Cornell Chronicle. Chronicle story link: http://www.news.cornell.edu/stories/Nov09/ARRAWeissPNAS.html

Media Contact:
Joe Schwartz
(607) 254-6235
Joe (dot) Schwartz (at) cornell (dot) edu

###


Read the full story at http://www.prweb.com/releases/Cornell_University/Cancer_Cell_Research/prweb3198014.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
2. Healthy restaurants help make us fat, says a new Cornell study
3. The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell
4. White House awards Weill Cornells Bruce McCandliss highest honor for early career scientists
5. Weill Cornell receives $2.4 million in grants from Gates Foundation to fight tuberculosis
6. NewYork-Presbyterian/Weill Cornell creates world-class cancer center
7. By color-coding atoms, new Cornell electron microscope promises big advance in materials analysis
8. $50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center
9. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
10. Weill Cornell receives funding to study creation of new elder abuse center
11. Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... “I Forgive You”: a fine examination of how God handles sin, including how to ... author, Stephen Miller, who, for over ten long years has been waiting to release this ... and Tobago, he has been serving the Lord for over twenty years, and he has ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children ... the simple and achievable answer. “The Land of More and More” is the creation ... in Angola, Indiana where he works with the children’s ministry department. , Michael ...
(Date:1/19/2017)... ... 2017 , ... Wells Pharmacy Network announced the completion of ... pharmacy located in Ocala, Florida. , Meeting the Needs of a Growing ... States for high-quality human anti-aging and wellness compounded medications, Wells Pharmacy ...
(Date:1/19/2017)... ... January 19, 2017 , ... Remote Medical Technologies ... impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. Compatible ... technology that delivers HD, dynamic, streaming ultrasound images and video to one or ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, ... $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro ... facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Fla. , Jan. 19, 2017  Sensus ... medical device company specializing in the treatment of ... as keloids, with superficial radiation therapy, today announced ... full year 2016 financial results on Thursday, February 2, ... Company will hold a conference call with the ...
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
Breaking Medicine Technology: